Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AUTO4 |
| Synonyms | |
| Therapy Description |
AUTO4 are autologous T-cells that have been engineered to express a chimeric antigen receptor (CAR) that targets the T-cell receptor beta constant 1 (TRBC1), potentially resulting in killing of TRBC1-expressing tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AUTO4 | AUTO-4|AUTO 4 | AUTO4 are autologous T-cells that have been engineered to express a chimeric antigen receptor (CAR) that targets the T-cell receptor beta constant 1 (TRBC1), potentially resulting in killing of TRBC1-expressing tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03590574 | Phase Ib/II | AUTO4 | Phase I/II Study Evaluating AUTO4 in Patients with TRBC1 Positive T Cell Lymphoma | Completed | GBR | ESP | 0 |